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Abstract 3 
CD58 is an adhesion molecule that is known to play a critical role in co-stimulation of 4 
effector cells and is intrinsic to immune synapse structure. Herein, we describe the first 5 
virally-encoded gene that inhibits CD58 surface expression. Human cytomegalovirus 6 
(HCMV) UL148 was necessary and sufficient to promote intracellular retention of CD58 7 
during HCMV infection. Blocking studies with antagonistic anti-CD58 mAb and an HCMV 8 
UL148 deletion mutant (HCMV∆UL148) with restored CD58 expression demonstrated that 9 
the CD2/CD58 axis was essential for the recognition of HCMV-infected targets by 10 
CD8+ HCMV-specific cytotoxic T lymphocytes (CTLs). Further, challenge of peripheral 11 
blood mononuclear cells ex vivo with HCMV∆UL148 increased both CTL and natural killer 12 
(NK) cell degranulation against HCMV-infected cells, including NK-driven antibody-13 
dependent cellular cytotoxicity, showing that UL148 is a modulator of the function of 14 
multiple effector cell subsets. Our data stress the impact of HCMV immune evasion 15 
functions on shaping the immune response, highlighting the capacity for their potential use 16 
in modulating immunity during the development of anti-HCMV vaccines and HCMV-based 17 
vaccine vectors. 18 
 19 
Significance statement  20 
HCMV is the major infectious cause of developmental disorders in babies due to its 21 
capacity to cross the placenta. HCMV is also a major pathogen in transplant recipients 22 
and HIV-AIDS patients. Despite inducing the strongest immune responses observed for 23 
any human pathogen, HCMV evades host defenses and persists for life. We report a novel 24 
viral stealth strategy. HCMV UL148 reduces surface expression of a key cell adhesion 25 
molecule (CD58), impairing the ability of NK and T cells to be activated by HCMV-infected 26 
cells. This is the first description of a viral gene targeting this pathway. Our findings 27 
highlight a role for CD58 in recognition of HCMV-infected cells and may be relevant for 28 
development of future antiviral therapies.  29 
  30 
 3 
\body 1 
Introduction 2 
Human cytomegalovirus (HCMV; species Human betaherpesvirus 5), is the major viral 3 
cause of congenital birth defects and an important pathogen capable of causing severe 4 
disease in immunocompromised and immune-naïve individuals. HCMV is noted for 5 
inducing the most potent cellular immune responses observed for any human pathogen. 6 
These responses, including expansions of cytotoxic T-lymphocytes (CTLs) and natural 7 
killer (NK) cells of a specific phenotype, are large and are maintained for life (reviewed in 8 
(1, 2)). HCMV, however, is not cleared by the host following primary infection. The 9 
mechanisms that underpin the ability of the virus to endure in the presence of such 10 
immunity has been the target of intense study, with the hope that the knowledge gained 11 
will inform the generation of anti-HCMV vaccines and also vaccine design, for which the 12 
maintenance of induced immune responses is paramount. Indeed, HCMV is being pursued 13 
as a vaccine vector in its own right as redirection of anti-CMV immunity can clear 14 
pathogens otherwise capable of persisting in their host (3, 4). The study of HCMV-encoded 15 
genes and proteins has revealed many strategies designed to avoid innate and adaptive 16 
immunity, which have defined a number of basic immune pathways essential to CTL and 17 
NK activity. These include at least four functions that inhibit HLA-I expression and ten that 18 
impair NK cell activation (reviewed in (5, 6)). 19 
 20 
CTLs and NK cells use the supramolecular adhesion complex (SMAC) at the immune 21 
synapse (IS) to interact with their targets. The SMAC is a tightly packed intercellular 22 
complex of adhesion molecules and receptor/ligand pairs where antigen presentation and 23 
signaling take place, which regulate the secretion of cytotoxic granules and cytokines from 24 
the effector cells (7-9). There are many descriptions of HCMV acting to prevent expression 25 
of activating ligands and promote the expression of inhibitory receptors on the target cell 26 
surface, but reports of immune evasion mechanisms able to impede formation of IS 27 
structure have been limited to remodeling of the target cell actin cytoskeleton (10).  28 
 29 
CD58 (LFA-3) on target cells acts to promote cell-to-cell adhesion and IS formation, and 30 
to provide a co-stimulatory signal through its receptor, CD2, on effectors (11-23). Recent 31 
studies have highlighted the importance of CD2 engagement for co-stimulation of CD4+ T-32 
cells in HCMV infection (24) and adaptive NK cells (25, 26), and have identified the 33 
CD2/CD58 axis as the primary co-stimulatory pathway for CD28-CD8+ CTLs (19, 27, 28). 34 
Cell surface expression of CD58 has been reported to be either upregulated (29, 30) or 35 
downregulated (31) by HCMV infection depending on the HCMV strain used. The aim of 36 
 4 
our study was to dissect this phenomenon, thereby determining the functional relevance 1 
of regulating CD58 expression on HCMV-infected cells. We describe the identification of 2 
the first viral-encoded gene responsible for downregulating CD58 and detail the broad 3 
impact of this novel function on both CTL and NK cell recognition in the context of HCMV 4 
infection. 5 
  6 
 5 
Results 1 
 2 
HCMV UL148 is a novel viral function down-regulating cell surface expression of 3 
CD58  4 
HCMV strain AD169 has previously been reported to upregulate CD58 (29, 30), whereas 5 
proteomic analysis with low passage HCMV strain Merlin has suggested the opposite (31). 6 
We confirmed these effects directly by flow cytometry (Fig.1). AD169 has suffered a 7 
spontaneous deletion in its genome during in vitro culture, involving a 15kb sequence 8 
designated the UL/b’ region (32).  We therefore investigated whether the function 9 
responsible for CD58 downregulation resided within UL/b’. Surface expression of CD58 10 
was analyzed in cells infected with a complete library of HCMV strain Merlin UL/b’ single 11 
gene deletion mutants (loss of function screen, Fig .2A) and an adenovirus vector library 12 
over-expressing each UL/b’ gene individually (gain of function screen, Fig.2B, Fig.S1). 13 
Both screens identified HCMV UL148 as the gene responsible, with loss of UL148 from 14 
HCMV strain Merlin (referred to as HCMV∆UL148) (Fig.S2) resulting in CD58 upregulation 15 
(Fig.2A, C), and ectopic expression of UL148 resulting in CD58 downregulation (Fig.2B, 16 
D).  17 
 18 
To screen for additional cell surface targets of UL148, we used plasma membrane profiling 19 
(PMP) of cells infected with HCMV, comparing Merlin to HCMV∆UL148. Filtering for 20 
proteins with Ig-, MHC, Cadherin, C-type lectin and TNF InterPro functional domains (31, 21 
33) was used to extend interrogation of UL148, focusing the analysis on immune receptors 22 
and ligands directly involved in NK or CTL functions (Fig.2E, Dataset S1 ‘Summary’). This 23 
proteomic analysis identified CD58 as the only cell surface molecule targeted by UL148 24 
that fell within these categories (Fig.2E). 25 
 26 
CD58 is retained within the cell by UL148 27 
Expression of CD58 was then studied during the course of HCMV infection. CD58 was 28 
gradually downregulated from the cell surface (Fig.1), whereas expression increased in 29 
whole cell lysates (Fig.3A). A faster migrating EndoH-sensitive CD58 glycoform 30 
accumulated in HCMV-infected cells and contrasted with the EndoH-resistant form 31 
detected in cells infected with HCMV∆UL148 (Fig.3A & B). This result is consistent with 32 
UL148 retaining CD58 as an immature precursor in the ER prior to processing through the 33 
Golgi complex. This model was further supported by co-immunoprecipitation of CD58 with 34 
UL148 from infected cells visualized either using immunoprecipitation with V5-tagged 35 
UL148 and Western blotting with anti-CD58 (Fig.3C) or in a global proteomic analysis 36 
 6 
using stable isotope labeling by amino acids in cell culture and immunoprecipitation 1 
(SILAC-IP) (Fig.S3). In conclusion, UL148 was both necessary and sufficient to mediate 2 
cell surface down-regulation and intracellular retention of CD58.  3 
 4 
UL148 is a potent modulator of CTL function 5 
The functional impact of CD58 regulation on CTL recognition was investigated in the 6 
context of HCMV infection by using HLA-A2-restricted CD8+ CTL lines generated to 7 
HCMV-IE1 VLEETSMVL (VLE) and HCMV-pp65 NLVPMVATV (NLV) peptides. These 8 
lines were tested by using CD107a degranulation assays and intracellular cytokine 9 
staining to detect cytokine production against autologous fibroblasts (uninfected or 10 
infected with Merlin or HCMVΔUL148) pulsed with a range of peptide concentrations. 11 
Absence of peptide led to minimal CTL activation. Peptide pulsing of uninfected cells 12 
resulted in a large increase in degranulation, which was significantly impaired by infection 13 
with HCMV strain Merlin. Deletion of UL148 resulted in recovery of degranulation in both 14 
CTL lines against HCMV-infected fibroblasts, including some experiments in which 15 
activation by HCMVΔUL148 was equivalent to that observed by peptide-pulsed uninfected 16 
cells (Fig.4A). A similar effect was observed for cytokine production in a third CTL line 17 
(Fig.S4). This occurred even though both Merlin and HCMVΔUL148 down-regulated HLA 18 
class-I evenly by more than tenfold (Fig.4B), indicating that these effects were independent 19 
of signals supplied through TCR recognition of HLA-I at that peptide dose. UL148 function 20 
could therefore compensate for more than tenfold differences in HLA-I expression. 21 
Significant differences in degranulation between Merlin and HCMVΔUL148 were observed 22 
over a narrow peptide range, with close to a doubling of the proportion of activated CD8+ 23 
CTLs occurring at 1μg/ml peptide, corresponding to a molar concentration of ~1μM. 24 
Doubling or decreasing the peptide dose by 20-fold overcame these differences (Fig.4C). 25 
 26 
CD58 co-stimulatory function occurs only in HCMV-infected cells 27 
The specificity of the UL148 effect on CD58 was explored by using a monoclonal antibody 28 
(mAb) that inhibited CD2/CD58 interaction. Application of anti-CD58 mAb resulted in 29 
significant blocking of CTL activity towards cells infected with HCMVΔUL148 over a range 30 
of peptide concentrations, in some cases reducing it to the levels observed when using 31 
Merlin-infected cells as targets (Fig.4D). We performed a more detailed analysis that 32 
combined all blocking experiments by normalizing data to the isotype control in each 33 
experiment. These combined data showed that blocking of CD58 produced an effect that 34 
was observable even against Merlin-infected targets, that became significantly different 35 
from the blocking of activation by HCMVΔUL148 at the peak peptide concentration 36 
 7 
(1μg/ml) (Fig.4E). Irrespective of higher levels of surface CD58 compared to HCMV-1 
infected targets, CTL activation measured by CD107 degranulation against uninfected 2 
cells could not be reduced by anti-CD58 mAb treatment, regardless of the peptide 3 
concentration used (Fig.4E,F). This differential effect of peptide loading and targets implies 4 
that HCMV-specific CD8+ CTLs are exquisitely sensitive to the context in which they 5 
receive activation signals, in that CD58-mediated co-stimulation became relevant only 6 
when these CTL were faced with an HCMV-infected target.  7 
 8 
UL148 significantly alters the ex vivo PBMC response to HCMV-infected cells 9 
The above data were generated using in vitro expanded T-cell lines. To test function in a 10 
more physiologically relevant setting, we challenged peripheral blood mononuclear cells 11 
(PBMC) ex vivo with fibroblasts infected with either Merlin or HCMV∆UL148 in the absence 12 
of exogenous peptide, comparing the degranulation responses of key effector cell subsets 13 
to the two viruses. In autologous assays and in the absence of peptide, CD3+CD8+ T-cells 14 
significantly increased their activation in response to HCMV∆UL148 in 3 of 9 subjects 15 
(Fig.4G). The CD2/CD58 axis has also been reported to be important in the activation of 16 
‘adaptive’ NK cells defined through expression of CD57 and NKG2C, the expansion of 17 
which is associated with previous HCMV infection (25, 26). Responses of ex vivo NK cells 18 
were tested in the presence of Cytotect (purified IgG from HCMV-seropositive subjects) or 19 
IgG from HCMV-seronegative individuals, included as a negative control to measure 20 
antibody-dependent cellular cytotoxicity (ADCC) as well as standard NK cell function. NK 21 
cell function was measured against both allogeneic human fetal foreskin fibroblasts 22 
(HFFFs) and autologous HCMV-infected skin fibroblasts. The greatest effect of removing 23 
UL148 was observed in an allogeneic ADCC setting with smaller, but significant increases 24 
in NK cell activation in the absence of Cytotect (Fig.5A,B, Fig.S4). In an autologous setting, 25 
removing UL148 significantly increased the recognition of HCMV-infected targets only in 26 
the presence of Cytotect (Fig.5C). Further analysis to phenotype the responsive subset 27 
indicated it resided in CD57+ NK cells (Fig.5D), with different subjects showing significantly 28 
different responses to ∆UL148 in one, other or both of CD57+NKG2C- and CD57+NKG2C+ 29 
NK populations (Fig.5E). CD57-NKG2C+ populations were not analyzed because they 30 
represented less than 3% of total CD3-CD56+ NK cells in all but one subject.  31 
 8 
Discussion 1 
 2 
HCMV has become a paradigm for viral immune evasion, with the study of the activities of 3 
its genes and proteins unveiling many aspects of immune function. We have now identified 4 
HCMV UL148 as the first recognized virally encoded downregulator of the cell adhesion 5 
molecule CD58, the intracellular retention of which reduces ex vivo activation of both CTLs 6 
and NK cells. This function is compatible with UL148 being an ER-resident type 1 7 
transmembrane glycoprotein containing an ER retention motif (RRR, at residues 314-316) 8 
(34, 35). The CD58/CD2 axis may become particularly important when infected target cells 9 
exhibit sub-optimal activation signals, for example due to the action of multiple HCMV-10 
encoded immune evasins. 11 
 12 
To date, UL148 has only been assigned one other viral function. In the HCMV strain 13 
TB40/E, UL148 disruption alters the ratio of glycoprotein H/glycoprotein L (gH/gL) 14 
complexes involved in virus entry, resulting in increased infectivity of epithelial cells, in part 15 
due to a direct interaction between UL148 and those complexes, and most likely in the ER 16 
(34). Our SILAC-IP analysis of proteins binding UL148 during infection with HCMV strain 17 
Merlin did not demonstrate a specific interaction with gH or gL (Fig.S3), suggesting 18 
underlying complexity in UL148 interactions associated with the HCMV strains used and 19 
their cellular tropisms. In this regard, there is also the possibility that the host proteins 20 
targeted by UL148 may differ depending on the cell type infected by HCMV, with our data 21 
derived from fibroblasts. The rhesus cytomegalovirus (RhCMV)-encoded ortholog of 22 
UL148 (Rh159) also has effects on virus tropism, although in this case disruption of the 23 
gene renders the virus unable to spread in epithelial cells (36). Further Rh159 exhibits 24 
immune regulatory functions, impairing the surface expression of the NKG2D ligands, 25 
MICA, MICB, ULBP1 and ULBP2 (37). Interestingly, although both Rh159 and UL148 act 26 
by binding to, and retaining intracellularly their target proteins, we and others have shown 27 
that UL148 does not bind any NKG2D ligands (37). In HCMV, these ligands are targeted 28 
by UL16, UL142, US9, US18 and US20 (5, 38). It will be interesting to determine whether 29 
there is a common theme of CMV-encoded ER-resident proteins that impact on both 30 
immune evasion and cell tropism. 31 
 32 
It is intriguing that blocking the CD2/CD58 interaction with an anti-CD58 monoclonal 33 
antibody did not inhibit effector activation by uninfected peptide-pulsed target cells, but did 34 
inhibit activation by HCMV-infected cells (Fig. 4D-F). A degree of inhibition of Merlin-35 
infected targets was expected since CD58 was still present albeit at a reduced level 36 
 9 
compared to HCMV∆UL148-infected cells (Fig.4B). The absence of any effect against 1 
uninfected targets (which had equivalent levels of CD58 to HCMV∆UL148-infected cells) 2 
is surprising. The multiple immune evasion mechanisms employed by HCMV, such as 3 
impairment of TCR signaling via HLA-I downregulation or via inhibitory receptors such as 4 
LIR-1 binding HCMV UL18 (39), alter the balance of activating and inhibitory signals 5 
received by effectors. Our data are consistent with the concept that there is much more 6 
complexity in the way CD8+ CTLs are activated by virally infected targets. HCMV-specific 7 
CTLs may be ‘re-tuned’ to activate when exposed to infected targets in response to virus-8 
encoded modulation of multiple activating and inhibitory ligands. 9 
 10 
Some speculative evidence for this idea may be gleaned from the phenotype of HCMV-11 
specific CTLs in vivo. HCMV drives massive, stable CD8+ CTL expansions, but it is 12 
interesting to note that the detailed phenotype and responsiveness of these cells is 13 
unusual compared to those described in classical models of T-cell differentiation (reviewed 14 
recently in (1)). For example, continuous in vitro stimulation by anti-CD3/anti-CD28 beads 15 
induces hallmarks of exhaustion in CD8+ T-cells (IL-7Rlo; and high levels of the immune 16 
cell inhibitor, programmed cell death protein 1 (PD1) (40)) that are reduced by co-17 
stimulation through anti-CD2 signals (28). In contrast, although HCMV-specific CD8+ CTLs 18 
have been reported as showing an exhausted/senescent and/or terminally differentiated 19 
phenotype, they exhibit proliferative capacity, the ability to change co-stimulatory and 20 
chemokine receptor-phenotype (41, 42) and do not show all the functionally associated 21 
classical markers of exhaustion such as PD1. They are generally PD1lo (39), whereas 22 
HCMV increases PD-L1 expression on infected cells (31), which would be consistent with 23 
HCMV-specific CTLs adapting to receive fewer inhibitory signals through the PD1/PD-L1 24 
axis. 25 
 26 
It is possible that immune adaptation occurs in all effector cells facing HCMV-infected 27 
targets, and that this leads to the unusual effector phenotypes observed in HCMV-28 
seropositive subjects. With regard to NK cells, an ‘adaptive’ NK subset that is 29 
CD57+NKG2C+FceR1- is expanded in HCMV-infected individuals and involved in ADCC 30 
(43, 44). In vitro expanded NKG2C+ NK cells exhibit higher levels of CD2 expression (45), 31 
which could aid activation in the face of lower levels of CD58 on target cells. We found 32 
that CD57+ NK cells exhibited enhanced ADCC in response to targets infected with 33 
HCMV∆UL148 compared to Merlin, with different subjects showing an impact on either or 34 
both NKG2C- and NKG2C+ NK cells within the CD57+ population (Fig.5). This is not 35 
unexpected, as NKG2C null individuals show CD57+ NK expansions following HCMV 36 
 10 
infection (2), which exhibit a requirement for CD2 co-stimulation in their responses (26). 1 
The data are consistent with expanded effector subsets in HCMV-seropositive individuals 2 
showing greater responsiveness to an activation pathway being inhibited by HCMV.  3 
 4 
Beyond CTL and NK cell recognition, it is notable that HCMV infection specifically induces 5 
cell surface expression of intercellular adhesion molecule 1 (ICAM1), which is reported to 6 
have an involvement equivalent to that of CD58 in formation of the SMAC (31, 46, 47). In 7 
the context of differential expression of such adhesion molecules. It is also tempting to 8 
speculate that ICAM1 may play an essential separate function in HCMV biology, and the 9 
specific downregulation of CD58 might provide an elegant mechanism for compensating 10 
for ICAM1 induction on infected cells. Indeed, ICAM1 is important in facilitating endothelial 11 
transmigration and permeability, and its induction could enhance dissemination of virus 12 
through host tissues (48) or play a role in direct cell-to-cell transfer of virus (49).  13 
 14 
Finally, our data highlights that significant ex vivo ADCC does occur against HCMV-15 
infected cells, even with HCMV strain Merlin, which encodes many NK cell immune 16 
evasion mechanisms and multiple Fc binding proteins (50). The impact of deleting UL148 17 
on ADCC and general immune responses suggest that HCMV might be manipulated to 18 
drive the activation of multiple different effector cell types, making the emerging field of 19 
HCMV-based vector design all the more important for vaccine development. 20 
  21 
 11 
Materials and Methods 1 
 2 
Cells 3 
Human fetal foreskin fibroblasts immortalized with human telomerase (HF-TERT), HF-4 
TERTs transfected with the coxsackie-adenovirus receptor (HF-CAR), and TERT-5 
immortalized donor dermal fibroblasts have been described previously (10). Cells were 6 
maintained in DMEM/10% fetal calf serum at 37°C/5% CO2.  7 
 8 
Viruses  9 
HCMV strain Merlin RCMV1111/KM192298 (RL13-, UL128-) (51), AD169 10 
varUK/BK000394, and Merlin recombinants containing single gene deletions in UL/b’ were 11 
generated as described previously (51) (SI1). Tagged HCMV recombinants were 12 
generated as described previously (38, 52) (SI1). Recombinant adenovirus vectors 13 
expressing individual HCMV UL/b’ genes were generated as described previously (53) 14 
and validated for expression (54). 15 
 16 
Antibodies and other reagents 17 
All reagentss were obtained from Biolegend, except Aqua live/dead dye (ThermoFisher), 18 
CD3-PE-Cy7 (clone UCHT-1, Beckman Coulter), CD8-APC-H7 (clone SK1, BD 19 
Biosciences), CD56-PE (clone N901, Beckman Coulter), CD58 (Abcam) CD107a-FITC 20 
(clone H4A3, BD Biosciences), MHC class-I (clone W6/32, Serotec) NKG2C-PE (clone 21 
134591, R&D systems), CD155 (5D1, (55)), actin (Sigma), V5-agarose (Abcam), V5 22 
(Serotec), anti-mouse-AF647 (ThermoFisher), anti-mouse-HRP (BioRad), anti-rabbit-HRP 23 
(BioRad), mouse IgG, UL141 (56), EndoH (NEB), PNGaseF (NEB). Other reagents were 24 
CD8-APC (clone HIT8a), CD56-BV605 (clone HCD56), CD57-APC (clone HNK-1), CD58 25 
(clone TS2/9), CD107a-PerCP-Cy5.5 (clone H4A3), TNF-BV421 (clone Mab11), IFN-26 
PE-Cy7 (4S.B3), MHC class-I-PE (clone W6/32). 27 
 28 
Flow cytometry 29 
For HCMV infections, adherent cells were harvested with TripLE Express (Thermofisher) 30 
or HyQTaseTM (GE Healthcare), stained in PBS/1%BSA buffer at 4°C with relevant 31 
antibodies, fixed with 4% paraformaldehyde and analyzed on an Accuri C6 flow cytometer 32 
(BD Biosciences) and with Accuri C6 software. For CD107a degranulation assays, data 33 
were gathered on an 11-color Attune NxT flow cytometer (ThermoFisher) and analyzed 34 
using Attune NxT or FlowJo V10 software. 35 
 36 
 12 
Immunoblotting 1 
Cells were lysed and boiled in reducing denaturing Nu-PAGE lysis buffer, and protein 2 
samples were separated on Nu-PAGE gels, transferred onto nitrocellulose membrane (GE 3 
Life Sciences), stained with relevant antibodies and Supersignal West Pico 4 
chemiluminescent substrate and imaged on Hyperfilm-MP (GE Life Sciences). In co-5 
immunoprecipitation experiments, cells were lysed in Triton X-100 lysis buffer, and protein 6 
complexes were captured with V5-agarose prior to SDS-PAGE and immunoblotting. 7 
 8 
NK and T-cell assays 9 
HCMV-specific CTL lines were grown from PBMCs stimulated with irradiated (6000 RADs) 10 
autologous, peptide-coated fibroblasts as described previously (10). Degranulation assays 11 
were performed as described previously (57), using effector:target ratios of 10:1. The 12 
targets were pulsed with peptide at various concentrations and the excess washed off, 13 
while for blocking studies, a final concentration of 10 µg/ml anti-CD58 mAb, TS2/9, was 14 
used. Statistical testing of data was carried out by using Graphpad Prism 5.0 for ANOVAs 15 
with Tukey’s multiple comparisons post-tests; p<0.05 was considered significant. Assays 16 
detecting ex vivo PBMC responses were carried out as described previously (58), with 17 
adaptation to a CD107a degranulation readout as described (57) and using multicolor flow 18 
cytometry to identify responding CD3+CD8+ T-cells, CD3-CD56+ NK cells and populations 19 
defined by expression of CD57 and NKG2C. Cytotect (Biotest) or IgG purified from HCMV-20 
seronegative subjects was incubated with targets for 10 mins at 37˚C at a concentration 21 
of 100 µg/ml prior to addition of an equivalent volume of effectors.  22 
 23 
Proteomics 24 
Proteomics was performed as described previously (31). Briefly, plasma membrane 25 
glycoproteins were oxidized with sodium metaperiodate and then biotinylated with 26 
aminoxybiotin (Cambridge Bioscience) prior to lysis of cells with Triton X-100. Biotinylated 27 
glycoproteins were captured with streptavidin agarose, and then washed, denatured, 28 
alkylated and digested on beads with Trypsin (Gibco). Peptides were fractionated by using 29 
strong cation exchange. Enriched peptides were labeled with tandem mass tag (TMT) 30 
reagents, combined at a 1:1 ratio, and then pre-fractionated by offline high-pH-reversed-31 
phase chromatography (Agilent). Mass spectrometry and data analysis were performed 32 
as described previously by using an Orbitrap Fusion. P-values were estimated using 33 
Benjamini-Hochberg-corrected significance A or Significance B values from Perseus 34 
version 1.2.0.16 (59). SILAC-IP experiments were conducted and analyzed as described 35 
previously (10). 36 
 13 
 1 
Ethics statement 2 
Healthy adult volunteers provided blood and dermal fibroblasts for this study after 3 
providing written informed consent. The study was approved by the Cardiff University 4 
School of Medicine Research Ethics Committee ref. nos: 10/20 and 16/52. 5 
 6 
Acknowledgements  7 
The study was supported by MRC and Wellcome Trust grants G1000236, MR/P001602/1, 8 
WT090323MA, MR/L008734/1 (ECYW, VV, SF, DR, CAF, SS, IM, MiP, RJS, GWW, PT), 9 
MC_UU_12014/3 (GSW, NMS, BL, AD), MEYS – NPS I – LO1413 (MP, ER), Czech 10 
Science Foundation project no. P206/12/G151 (BV), Wellcome Trust Senior Clinical 11 
Research Fellowship 108070 (MPW), and Wellcome Trust Principal Research Fellowship 12 
101835 (PJL). 13 
  14 
 14 
References 1 
1. Klenerman P & Oxenius A (2016) T cell responses to cytomegalovirus. Nat Rev 2 
Immunol 16(6):367-377. 3 
2. Goodier MR, et al. (2014) Rapid NK cell differentiation in a population with near-4 
universal human cytomegalovirus infection is attenuated by NKG2C deletions. Blood 5 
124(14):2213-2222. 6 
3. Hansen SG, et al. (2013) Cytomegalovirus vectors violate CD8+ T cell epitope 7 
recognition paradigms. Science 340(6135):1237874. 8 
4. Hansen SG, et al. (2013) Immune clearance of highly pathogenic SIV infection. Nature 9 
502(7469):100-104. 10 
5. Wilkinson GW, et al. (2008) Modulation of natural killer cells by human 11 
cytomegalovirus. J Clin Virol 41(3):206-212. 12 
6. Halenius A, Gerke C, & Hengel H (2015) Classical and non-classical MHC I molecule 13 
manipulation by human cytomegalovirus: so many targets-but how many arrows in 14 
the quiver? Cell Mol Immunol 12(2):139-153. 15 
7. Davis DM, et al. (1999) The human natural killer cell immune synapse. Proc Natl Acad 16 
Sci U S A 96(26):15062-15067. 17 
8. Grakoui A, et al. (1999) The immunological synapse: a molecular machine controlling 18 
T cell activation. Science 285(5425):221-227. 19 
9. Monks CR, Freiberg BA, Kupfer H, Sciaky N, & Kupfer A (1998) Three-dimensional 20 
segregation of supramolecular activation clusters in T cells. Nature 395(6697):82-86. 21 
10. Stanton RJ, et al. (2014) HCMV pUL135 remodels the actin cytoskeleton to impair 22 
immune recognition of infected cells. Cell Host Microbe 16(2):201-214. 23 
11. Beyers AD, Spruyt LL, & Williams AF (1992) Molecular associations between the T-24 
lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and 25 
CD5. Proc Natl Acad Sci U S A 89(7):2945-2949. 26 
12. Bierer BE & Hahn WC (1993) T cell adhesion, avidity regulation and signaling: a 27 
molecular analysis of CD2. Semin Immunol 5(4):249-261. 28 
13. Brown MH, Cantrell DA, Brattsand G, Crumpton MJ, & Gullberg M (1989) The CD2 29 
antigen associates with the T-cell antigen receptor CD3 antigen complex on the surface 30 
of human T lymphocytes. Nature 339(6225):551-553. 31 
14. Davis SJ, Ikemizu S, Wild MK, & van der Merwe PA (1998) CD2 and the nature of 32 
protein interactions mediating cell-cell recognition. Immunol Rev 163:217-236. 33 
15. Dustin ML, Selvaraj P, Mattaliano RJ, & Springer TA (1987) Anchoring mechanisms for 34 
LFA-3 cell adhesion glycoprotein at membrane surface. Nature 329(6142):846-848. 35 
16. Gassmann M, Amrein KE, Flint NA, Schraven B, & Burn P (1994) Identification of a 36 
signaling complex involving CD2, zeta chain and p59fyn in T lymphocytes. Eur J 37 
Immunol 24(1):139-144. 38 
17. Holter W, Schwarz M, Cerwenka A, & Knapp W (1996) The role of CD2 as a regulator 39 
of human T-cell cytokine production. Immunol Rev 153:107-122. 40 
18. Kaizuka Y, Douglass AD, Vardhana S, Dustin ML, & Vale RD (2009) The coreceptor CD2 41 
uses plasma membrane microdomains to transduce signals in T cells. J Cell Biol 42 
185(3):521-534. 43 
19. Leitner J, Herndler-Brandstetter D, Zlabinger GJ, Grubeck-Loebenstein B, & 44 
Steinberger P (2015) CD58/CD2 Is the Primary Costimulatory Pathway in Human 45 
CD28-CD8+ T Cells. J Immunol 195(2):477-487. 46 
20. Meuer SC, et al. (1984) An alternative pathway of T-cell activation: a functional role 47 
for the 50 kd T11 sheep erythrocyte receptor protein. Cell 36(4):897-906. 48 
21. Selvaraj P, et al. (1987) The T lymphocyte glycoprotein CD2 binds the cell surface 49 
ligand LFA-3. Nature 326(6111):400-403. 50 
 15 
22. Siliciano RF, Pratt JC, Schmidt RE, Ritz J, & Reinherz EL (1985) Activation of cytolytic 1 
T lymphocyte and natural killer cell function through the T11 sheep erythrocyte 2 
binding protein. Nature 317(6036):428-430. 3 
23. Yang JJ, Ye Y, Carroll A, Yang W, & Lee HW (2001) Structural biology of the cell 4 
adhesion protein CD2: alternatively folded states and structure-function relation. Curr 5 
Protein Pept Sci 2(1):1-17. 6 
24. Shiao SL, et al. (2007) Human effector memory CD4+ T cells directly recognize 7 
allogeneic endothelial cells in vitro and in vivo. J Immunol 179(7):4397-4404. 8 
25. Rolle A, et al. (2016) CD2-CD58 interactions are pivotal for the activation and function 9 
of adaptive natural killer cells in human cytomegalovirus infection. Eur J Immunol 10 
46(10):2420-2425. 11 
26. Liu LL, et al. (2016) Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell 12 
Responses Revealed in NKG2C-Deficient Humans. Cell Rep 15(5):1088-1099. 13 
27. Bruns T, et al. (2015) CMV infection of human sinusoidal endothelium regulates 14 
hepatic T cell recruitment and activation. J Hepatol 63(1):38-49. 15 
28. McKinney EF, Lee JC, Jayne DR, Lyons PA, & Smith KG (2015) T-cell exhaustion, co-16 
stimulation and clinical outcome in autoimmunity and infection. Nature 17 
523(7562):612-616. 18 
29. Grundy JE & Downes KL (1993) Up-regulation of LFA-3 and ICAM-1 on the surface of 19 
fibroblasts infected with cytomegalovirus. Immunology 78(3):405-412. 20 
30. Fletcher JM, Prentice HG, & Grundy JE (1998) Natural killer cell lysis of 21 
cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell 22 
surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with 23 
the CMV-induced down-regulation of cell surface class I HLA. J Immunol 161(5):2365-24 
2374. 25 
31. Weekes MP, et al. (2014) Quantitative temporal viromics: an approach to investigate 26 
host-pathogen interaction. Cell 157(6):1460-1472. 27 
32. Cha TA, et al. (1996) Human cytomegalovirus clinical isolates carry at least 19 genes 28 
not found in laboratory strains. J Virol 70(1):78-83. 29 
33. Vivier E, Tomasello E, Baratin M, Walzer T, & Ugolini S (2008) Functions of natural 30 
killer cells. Nat Immunol 9(5):503-510. 31 
34. Li G, Nguyen CC, Ryckman BJ, Britt WJ, & Kamil JP (2015) A viral regulator of 32 
glycoprotein complexes contributes to human cytomegalovirus cell tropism. Proc Natl 33 
Acad Sci U S A 112(14):4471-4476. 34 
35. ELM (2015) The Eukaryotic Linear Motif resource for functional sites in proteins. 35 
36. Lilja AE, Chang WL, Barry PA, Becerra SP, & Shenk TE (2008) Functional genetic 36 
analysis of rhesus cytomegalovirus: Rh01 is an epithelial cell tropism factor. J Virol 37 
82(5):2170-2181. 38 
37. Sturgill ER, et al. (2016) Natural Killer Cell Evasion Is Essential for Infection by Rhesus 39 
Cytomegalovirus. PLoS Pathog 12(8):e1005868. 40 
38. Fielding CA, et al. (2014) Two novel human cytomegalovirus NK cell evasion functions 41 
target MICA for lysosomal degradation. PLoS Pathog 10(5):e1004058. 42 
39. Hertoghs KM, et al. (2010) Molecular profiling of cytomegalovirus-induced human 43 
CD8+ T cell differentiation. J Clin Invest 120(11):4077-4090. 44 
40. Francisco LM, Sage PT, & Sharpe AH (2010) The PD-1 pathway in tolerance and 45 
autoimmunity. Immunol Rev 236:219-242. 46 
41. Gandhi MK, et al. (2003) Late diversification in the clonal composition of human 47 
cytomegalovirus-specific CD8+ T cells following allogeneic hemopoietic stem cell 48 
transplantation. Blood 102(9):3427-3438. 49 
42. Waller EC, et al. (2007) Differential costimulation through CD137 (4-1BB) restores 50 
proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) 51 
CD8(+) T cells. Blood 110(13):4360-4366. 52 
 16 
43. Guma M, et al. (2004) Imprint of human cytomegalovirus infection on the NK cell 1 
receptor repertoire. Blood 104(12):3664-3671. 2 
44. Guma M, et al. (2006) Expansion of CD94/NKG2C+ NK cells in response to human 3 
cytomegalovirus-infected fibroblasts. Blood 107(9):3624-3631. 4 
45. Beziat V, et al. (2013) NK cell responses to cytomegalovirus infection lead to stable 5 
imprints in the human KIR repertoire and involve activating KIRs. Blood 6 
121(14):2678-2688. 7 
46. Kronschnabl M & Stamminger T (2003) Synergistic induction of intercellular adhesion 8 
molecule-1 by the human cytomegalovirus transactivators IE2p86 and pp71 is 9 
mediated via an Sp1-binding site. J Gen Virol 84(Pt 1):61-73. 10 
47. Huppa JB & Davis MM (2003) T-cell-antigen recognition and the immunological 11 
synapse. Nat Rev Immunol 3(12):973-983. 12 
48. Bentz GL, et al. (2006) Human cytomegalovirus (HCMV) infection of endothelial cells 13 
promotes naive monocyte extravasation and transfer of productive virus to enhance 14 
hematogenous dissemination of HCMV. J Virol 80(23):11539-11555. 15 
49. Murrell I, et al. (2017) The pentameric complex drives immunologically covert cell-cell 16 
transmission of wild-type human cytomegalovirus. Proc Natl Acad Sci U S A 17 
114(23):6104-6109. 18 
50. Corrales-Aguilar E, et al. (2014) Human cytomegalovirus Fcgamma binding proteins 19 
gp34 and gp68 antagonize Fcgamma receptors I, II and III. PLoS Pathog 20 
10(5):e1004131. 21 
51. Stanton RJ, et al. (2010) Reconstruction of the complete human cytomegalovirus 22 
genome in a BAC reveals RL13 to be a potent inhibitor of replication. J Clin Invest 23 
120(9):3191-3208. 24 
52. Murrell I, et al. (2016) Genetic Stability of Bacterial Artificial Chromosome-Derived 25 
Human Cytomegalovirus during Culture In Vitro. J Virol 90(8):3929-3943. 26 
53. Stanton RJ, McSharry BP, Armstrong M, Tomasec P, & Wilkinson GW (2008) Re-27 
engineering adenovirus vector systems to enable high-throughput analyses of gene 28 
function. Biotechniques 45(6):659-662, 664-658. 29 
54. Seirafian S (2012) An analysis of human cytomegalovirus gene usage. PhD thesis, 30 
Cardiff University (orca.cf.ac.uk/46644/). 31 
55. Aoki J, Koike S, Ise I, Sato-Yoshida Y, & Nomoto A (1994) Amino acid residues on 32 
human poliovirus receptor involved in interaction with poliovirus. J Biol Chem 33 
269(11):8431-8438. 34 
56. Tomasec P, et al. (2005) Downregulation of natural killer cell-activating ligand CD155 35 
by human cytomegalovirus UL141. Nat Immunol 6(2):181-188. 36 
57. Prod'homme V, et al. (2007) The human cytomegalovirus MHC class I homolog UL18 37 
inhibits LIR-1+ but activates LIR-1- NK cells. J Immunol 178(7):4473-4481. 38 
58. Wang EC, et al. (2002) UL40-mediated NK evasion during productive infection with 39 
human cytomegalovirus. Proc Natl Acad Sci U S A 99(11):7570-7575. 40 
59. Cox J & Mann M (2008) MaxQuant enables high peptide identification rates, 41 
individualized p.p.b.-range mass accuracies and proteome-wide protein 42 
quantification. Nat Biotechnol 26(12):1367-1372. 43 
 44 
  45 
 17 
Figure Legends  1 
Figure 1: HCMV infection down-regulates cell surface CD58 2 
Human fibroblast (HF-TERT) cells infected with (A) HCMV strain Merlin or (B) strains 3 
Merlin or AD169 (MOI=5) or (A, B) mock-infected, and analyzed at the indicated time 4 
points post-infection by flow cytometry for cell surface expression of CD58 and MHC class-5 
I. cIgG = isotype control IgG. 6 
 7 
Figure 2: CD58 cell surface down-regulation is mediated by UL148 8 
(A) Human fibroblast (HF-TERT) cells infected with a library of HCMV strain Merlin deletion 9 
mutants, (MOI=5, 72h post infection) and (B) human fibroblast (HF-CAR) cells infected 10 
with a library of adenovirus vectors encoding HCMV strain Merlin UL/b’ genes, (MOI=5, 11 
48h post-infection) as indicated were analyzed by flow cytometry for cell surface 12 
expression of CD58 and MHC class-I. MHC class-I down-regulation, which is a standard 13 
marker of HCMV infection, was used for quality control. Median fluorescence intensity 14 
(MFI) values relative to control cells (set to 1) are shown. (C, D) Representative plots from 15 
panels (A) and (B), respectively. (E) Scatterplot of cell surface proteins modulated by 16 
UL148 analyzed by plasma membrane profiling. The complete data spreadsheet is shown 17 
in SI3. Proteins that contained Ig-/ MHC/ Cadherin/ C-type lectin/ TNF InterPro functional 18 
domains were included in the scatterplot. Significance B was used to estimate p values 19 
(59). The complete data spreadsheet is shown in Dataset S1. 20 
 21 
Figure 3: UL148 retains immature CD58 intracellularly and interacts with CD58 22 
Human fibroblast (HF-TERT) cells were infected (MOI=5) with HCMV strain Merlin 23 
(HCMV) or a UL148 deletion mutant (ΔUL148) and lysates were analyzed by 24 
immunoblotting (A) at the indicated time points post-infection or (B) 72h post-infection. 25 
EndoH or PNGaseF glycosidases were used as indicated. CD155, which is known to be 26 
retained in the ER by HCMV UL141 and actin were used as controls. (C) HF-TERT cells 27 
were infected with HCMV strain Merlin (HCMV) or HCMV recombinants expressing V5-28 
tagged UL148 (HCMVUL148.V5) or UL141 (HCMVUL141.V5) and whole cell lysates 29 
(WCL) were analyzed by immunoblotting or co-immunoprecipitation (V5-IP). The known 30 
interaction between CD155 and UL141 served as a control. 31 
 32 
Figure 4: UL148 modulates CTL function against HCMV-infected cells through CD58 33 
(A) Human dermal fibroblast (D007) cells were infected with HCMV strain Merlin (HCMV) 34 
or an UL148 deletion mutant (ΔUL148) (MOI=10, 72h). Cells were pulsed with VLE or NLV 35 
peptide at 1 µg/ml and used in standard CD107 degranulation assay as targets for VLE- 36 
 18 
or NLV-specific T-cell lines generated from donor D007. Means + SEM of quadruplicate 1 
samples are shown.  (B) Expression of CD58 and MHC class-I on D007 cells. (C) 2 
Summary of HCMV vs HCMVΔUL148 data from 5 separate experiments standardizing 3 
values to the mock-infected control at the peptide concentrations indicated. One-way 4 
ANOVA with Tukey (for >5 means) multiple comparison post-hoc tests showed 5 
significance differences between HCMV and HCMVΔUL148 at *** p<0.001. (D) Effect of 6 
anti-CD58 mAb or an isotype control added at the start of assays to a concentration of 7 
10µg/ml at the indicated peptide concentrations. Means + SEM of quadruplicate samples 8 
are shown. (E) Summary data of 3 different blocking experiments following standardization 9 
to isotype control values. (F) Further blocking assay on uninfected fibroblasts at lower 10 
concentrations of peptide pulsing. One-way ANOVA with Tukey (for>5 means) multiple 11 
comparison post-hoc tests showed significance differences at ** p<0.01 and *** p<0.001. 12 
(G) Degranulation of CD3+CD8+ T-cells in PBMC of 9 HCMV-seropositive donors 13 
challenged with autologous fibroblasts infected with HCMV strain Merlin or HCMV∆UL148 14 
in the absence of peptide (MOI=10, 72h). Points are means of triplicate samples. Paired 15 
t-Test showed the p value indicated. # marks the 3 of 9 donors showing significant 16 
differences (p<0.05) when comparing responses between Merlin and HCMV∆UL148 using 17 
one-way ANOVA with Tukey multiple comparison post-hoc tests with %change from the 18 
Merlin response indicated in brackets.  19 
 20 
Figure 5: Deletion of UL148 alters the response of NK cells 21 
Fibroblasts were infected with HCMV strain Merlin (HCMV) or a UL148 deletion mutant 22 
(ΔUL148) (MOI=10, 72h). Cytotect or HCMV-negative IgG was added to a final 23 
concentration of 50 µg/ml. The cells were used to stimulate PBMCs from healthy donors 24 
stimulated overnight with 1000 IU/ml IFN. CD3-CD56+ NK cell responses to allogeneic 25 
fibroblast (HF-TERT) cells from (A) a representative donor and (B) ten donors comparing 26 
responses with control HCMV-negative IgG and Cytotect. CD3-CD56+ NK cell responses 27 
to autologous dermal fibroblasts are shown in (C) with a summary of nine donors 28 
comparing responses with control HCMV-negative IgG and Cytotect. Allogeneic ADCC 29 
responses were further split into (D) CD57- and CD57+ NK responses, and (E) CD57-30 
NKG2C-, CD57+NKG2C+ and CD57+NKG2C- NK responses in 7 to 9 subjects. Data 31 
passed D’Agostino & Pearson omnibus normality testing. Points are mean of triplicate 32 
cultures. Paired t-Test showed the indicated significance p values. # marks donors 33 
showing significant differences (p<0.05) when comparing individual responses between 34 
Merlin and HCMV∆UL148 using one-way ANOVA with Tukey multiple comparison post-35 
hoc tests. (2C-) indicates NKG2C- subjects, detected by flow cytometry.  36 
 19 
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Supplemental Information Legends 1 
Figure S1: Details of the library of HCMV recombinants containing single gene 2 
deletions 3 
Recombinant HCMVs (RCMVs) were generated by recombineering of the strain Merlin 4 
bacterial artificial chromosome BAC1111/KM192298 (RL13-, UL128-) (Stanton RJ, et al. 5 
(2010). J Clin Invest 120: 3191-3208). Whole-genome consensus sequences of passage 6 
1 of each RCMV were derived by using the Illumina platform as described previously 7 
(Fielding CA, et al. (2014). PLoS Pathog 10: e1004058), and were deposited in GenBank. 8 
Deleted regions are shown between slashes in lower case, with the initiation codon 9 
underlined, and did not always include the whole protein-coding region. Except for the 10 
differences noted, the viruses were genetically identical to that recovered from the parental 11 
BAC (RCMV1111/KM192298). 12 
* middle G tract near right end of US is 1 bp shorter 13 
** contains an 1190 bp E. coli insertion element IS150 plus a 3 bp duplication at the right 14 
end inserted into US11. This insertion was considered irrelevant to this study, but the 15 
recombinant was not banked for further use and the sequence was not deposited in 16 
GenBank. 17 
 18 
Two further recombinants (not listed) were also constructed and their whole-genome 19 
sequences verified. To insert a V5 tag after UL148 (RCMV2084), a recombineering 20 
cassette comprising KanR/rpsL/lacZ was amplified and inserted into the 5’ end of UL148 21 
by using primers UL148 SacB Forward 22 
GCATTCTCGAGACGTGGCGACGTGGATTTCTTGCTATGTCCGCGAACGACGTGTGA23 
CGAGGACGTGGTTTCCGCAAGCCTCCTGTGACGGAAGATCACTT, UL148 Sac B 24 
Reverse 25 
TCAACACATTGCTGATTACAATGATGGCGGCGATATGGGCTCGCGTTTTGATAACCT26 
ACCTGGTGTCGCGGCGTCGGTAGCTGAGGTTCTTATGGCTCTT-3’. In a second 27 
round of recombineering, this cassette was removed and replaced by a V5 tag by using 28 
the complementary primers 29 
TGCTATGTCCGCGAACGACGTGTGACGAGGACGTGGTTTCCGCAAGCCTTTACGTA30 
GAATCAAGACCTAGGAGCGGGTTAGGGATTGGCTTACCAGCGCT 31 
And 32 
GGCGATATGGGCTCGCGTTTTGATAACCTACCTGGTGTCGCGGCGTCGGAGCGCT33 
GGTAAGCCAATCCCTAACCCGCTCCTAGGTCTTGATTCTACGTAA 34 
(V5 tag and linker underlined). To insert a V5 tag after UL141 (RCMV2022), the 35 
KanR/rpsL/lacZ was amplified and inserted at the end of UL141 using primers 36 
 25 
AGGGGACGACGAGGCGGTGAGGGCTATCGACGCCTACCGACTTACGATAGTTACC1 
CCGGTGTTAAAAAGATGAAGAGGCCTGTGACGGAAGATCACTTCG and 2 
GCATATTTTAATCACACTATTCACATTTCACACACTGCATTTTTTAACATCTTATTTTT3 
TTATTTTATGCGTGTTCTCACTGAGGTTCTTATGGCTCTTG 4 
(regions of homology to UL141 underlined). This cassette was then removed and replaced 5 
with a V5 tag, using primers 6 
GACGCCTACCGACTTACGATAGTTACCCCGGTGTTAAAAAGATGAAGAGGGGCTCC7 
GGGGGGTCGGGTGGAAGTGGCGGTAAGCCAATCCCTAACCCGCT 8 
And 9 
ACACACTGCATTTTTTAACATCTTATTTTTTTATTTTATGCGTGTTCTCACGTAGAATC10 
AAGACCTAGGAGCGGGTTAGGGATTGGCTTACCGCCACTTC (complementary 11 
regions that overlapped to generate the V5 tag underlined).  12 
 13 
Figure S2: Transcriptome profiles of HCMV strain Merlin (RCMV1111) and ΔUL148 14 
(RCMV2035) 15 
(A) Whole-cell RNA was isolated from human fibroblast (HF-TERT) cells infected with 16 
HCMV strain Merlin (RCMV1111) or a UL148 deletion mutant ΔUL148 (RCMV2035) at 72 17 
h post-infection. Transcriptome profiles were derived from directional Illumina RNA-Seq 18 
data generated from polyadenylated RNA. The genome is shown in five sections, with the 19 
inverted repeats shaded grey. Protein-coding regions and non-coding RNAs are shown by 20 
color- and white-shaded arrows, respectively, with gene nomenclature below, and introns 21 
as narrow white bars connecting exons. The colours of protein-coding regions indicate 22 
conservation among alpha-, beta- and gammaherpesviruses (core genes) or between 23 
beta- and gammaherpesviruses (subcore genes), with certain noncore genes grouped into 24 
related families. The yellow windows depict transcription profiles for rightward (magenta) 25 
and leftward (cyan) transcripts. The extent of transcription is plotted as log10 of the number 26 
of reads per nucleotide (calculated by Bowtie2 assembly against the RCMV2035 27 
sequence) per million viral reads, the overall number of reads for RCMV2035) being 28 
normalised to that for RCMV1111. The number of viral reads (76 nucleotides) in the 29 
RCMV1111 and RCMV2035 datasets was 11,857,464 (48% of the total) and 12,178,576 30 
(52%), respectively. Among the regions containing zero reads (scored -2) is UL148 in 31 
RCMV2035 (boxed). Except for UL148, the transcriptome profile of RCMV2035 was very 32 
similar to that of RCMV1111. (B) Histogram showing the relative proportion (%) of 33 
normalized sequence read counts mapping to individual HCMV protein-coding regions and 34 
noncoding RNAs in RCMV2035 compared with RCMV1111. In this experiment, and 35 
excluding UL148, transcription levels of the protein-coding regions and non-coding RNAs 36 
 26 
were 105±16% of those in RCMV1111, ranging from 57% (UL146) to 183% (the region 1 
common to IRS1 and TRS1). Only UL148 was differentially expressed >2-fold. 2 
 3 
Figure S3: Identification of cellular proteins interacting with UL148 via SILAC-IP 4 
SILAC-labelled HFFF-TERT cells were infected (MOI=5, 72h) with unmodified HCMV 5 
strain Merlin (light-labeled cells), HCMVUL141.V5 (medium-labeled cells) or 6 
HCMVUL148.V5 (heavy-labeled cells) followed by immunoprecipitation of mixed lysates 7 
with anti-V5. Enriched proteins were digested with trypsin then subjected to mass 8 
spectrometry. To identify proteins that specifically interact with HCMV UL148, the following 9 
filters were employed: UL148:wt ratio of >2 and UL148:UL141 ratio of >2. UL141 served 10 
as an irrelevant control and did not interact with UL148 (heavy : light ratio = 1.3). 11 
Significance A was used to estimate p-values, which were adjusted for multiple hypothesis 12 
testing using the method of Benjamini-Hochberg (59).  13 
 14 
Figure S4: Effect of UL148 on cytokine production 15 
Autologous skin fibroblasts were infected with Merlin (HCMV) or a UL148 deletion mutant 16 
(∆UL148) ( MOI =10, 72h) and then used as targets against a CD8+ T-cell line or PBMCs. 17 
CD107a degranulation and intracellular cytokine staining for IFN and TNF were 18 
measured after 6h using standard procedures (Becton Dickinson). (A, B) Two separate 19 
experiments on a CD8+ T-cell line (D009-VTE) at a cognate peptide dose of 1 µg/ml. (C) 20 
PBMC data gating on CD57+CD3-CD56+ NK cells with targets in the presence of Cytotect. 21 
MFI = median fluorescence intensity for positive cells. Mean + SEM of quadruplicates 22 
shown. Two-way ANOVA comparing all means showed significance at *p<0.05, **p<0.01, 23 
***p<0.001. 24 
 25 
Dataset S1: Mass spectrometric analysis comparing Merlin and Merlin∆UL148 26 
Excel spreadsheet, no figure legend provided. 27 
 28 
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